

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 6-K**

---

**Report of Foreign Private Issuer  
Pursuant to Rule 13a-16 or 15d-16  
Under the Securities Exchange Act of 1934**

**For the month of October 2021**

**Commission File Number 001-40316**

---

**VECTIVBIO HOLDING AG**  
(Exact name of registrant as specified in its charter)

---

**Aeschenvorstadt 36  
4051 Basel  
Switzerland**  
(Address of principal executive offices)

---

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

---

VectivBio Holding AG is submitting this Report on Form 6-K to furnish its (i) unaudited interim condensed consolidated statement of financial position as of June 30, 2021 and (ii) unaudited interim condensed consolidated statement of income (loss) for the six months ended June 30, 2021, which are furnished herewith as Exhibit 99.1 and Exhibit 99.2, respectively, to this Report on Form 6-K.

Exhibits

|                             |  |
|-----------------------------|--|
| <a href="#"><u>99.1</u></a> | <a href="#"><u>Unaudited Interim Condensed Consolidated Statement of Financial Position for the Six Months Ended June 30, 2021</u></a> |
| <a href="#"><u>99.2</u></a> | <a href="#"><u>Unaudited Interim Condensed Consolidated Statement of Income (Loss) for the Six Months Ended June 30, 2021</u></a>      |

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**VECTIVBIO HOLDING AG**

October 29, 2021

By:           /s/ Claudia D'Augusta          

Claudia D'Augusta

Chief Financial Officer

VectivBio Holding AG

UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

| In thousands of USD                                  | As of,         |                   |
|--|----------------|-------------------|
|  | June 30, 2021  | December 31, 2020 |
| <b>ASSETS</b>  |                |                   |
| <b>NON-CURRENT ASSETS</b>                            |                |                   |
| Property, plant and equipment                        | 115            | 173               |
| Goodwill   | 918            | 901               |
| Intangible assets                                    | 22,171         | 21,758            |
| Right-of-use assets                                  | 98             | 114               |
| Financial assets                                     | 61             | 64                |
| <b>Total non-current assets</b>                      | <b>23,363</b>  | <b>23,010</b>     |
| <b>CURRENT ASSETS</b>                                |                |                   |
| Other current receivables                            | 523            | 963               |
| Other current assets                                 | 6,706          | 6,417             |
| Cash and cash equivalents                            | 144,610        | 40,172            |
| <b>Total current assets</b>                          | <b>151,839</b> | <b>47,552</b>     |
| <b>Total assets</b>                                  | <b>175,202</b> | <b>70,562</b>     |
| <b>EQUITY AND LIABILITIES</b>                        |                |                   |
| <b>EQUITY</b>  |                |                   |
| Net parent investment                                | —              | —                 |
| Share capital  | 1,856          | 1,370             |
| Reserves   | 242,419        | 101,933           |
| Accumulated losses                                   | (103,873)      | (71,065)          |
| <b>Total equity</b>                                  | <b>140,402</b> | <b>32,238</b>     |
| <b>NON-CURRENT LIABILITIES</b>                       |                |                   |
| Lease liabilities                                    | —              | 4                 |
| Net pension liabilities                              | 2,997          | 3,557             |
| <b>Total non-current liabilities</b>                 | <b>2,997</b>   | <b>3,561</b>      |
| <b>CURRENT LIABILITIES</b>                           |                |                   |
| Current liabilities related to business combinations | 20,000         | —                 |
| Contingent consideration liabilities                 | —              | 19,140            |
| Trade payables                                       | 3,062          | 9,490             |
| Accrued expenses                                     | 7,897          | 5,247             |
| Other current liabilities                            | 745            | 774               |
| Lease liabilities                                    | 99             | 112               |
| <b>Total current liabilities</b>                     | <b>31,803</b>  | <b>34,763</b>     |
| <b>Total liabilities</b>                             | <b>34,800</b>  | <b>38,324</b>     |
| <b>Total equity and liabilities</b>                  | <b>175,202</b> | <b>70,562</b>     |



VectivBio Holding AG

UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS)

| In thousands of United States dollars ("USD")                                   | Six Month Ended<br>June 30, |                 |
|---|-----------------------------|-----------------|
|   | 2021                        | 2020            |
| <b>CONSOLIDATED STATEMENTS OF OPERATIONS</b>                                    |                             |                 |
| Research and development expenses   | (26,494)                    | (10,660)        |
| General and administrative expenses   | (19,097)                    | (5,405)         |
| <b>Operating loss</b>   | <b>(45,591)</b>             | <b>(16,065)</b> |
| Finance income  | —                           | 15              |
| Finance expense   | (23)                        | (1,096)         |
| Foreign exchange differences, net   | 496                         | (517)           |
| <b>Loss before income taxes</b>   | <b>(45,118)</b>             | <b>(17,677)</b> |
| Income taxes  | —                           | —               |
| <b>Net loss</b>   | <b>(45,118)</b>             | <b>(17,677)</b> |
| Remeasurement of net pension liabilities  | 508                         | (511)           |
| <b>Total items that will not be reclassified subsequently to profit or loss</b> | <b>508</b>                  | <b>(670)</b>    |
| Exchange differences arising on translation of foreign operations               | (113)                       | (670)           |
| <b>Total items that may be reclassified subsequently to profit or loss</b>      | <b>(113)</b>                | <b>(670)</b>    |
| <b>Total other comprehensive loss, net of income tax</b>                        | <b>395</b>                  | <b>(1,181)</b>  |
| <b>Total comprehensive loss</b>   | <b>(44,723)</b>             | <b>(18,858)</b> |
| <b>LOSS PER SHARE</b>   |                             |                 |
| Basic and diluted loss per share (in USD)                                       | <b>(2.08)</b>               | <b>(1.85)</b>   |